Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial
Posted innews Oncology Pathology & Lab Medicine

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring showing near-universal clearance post-therapy.
PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Posted inGastroenterology news Oncology

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefining neoadjuvant standards for this aggressive malignancy.
Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer
Posted innews Oncology

Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer

A randomized phase II trial of the bispecific HER2-directed ADC TQB2102 (n=104) showed robust total pathologic complete response rates (tpCR 57.7–76.9% across cohorts) with manageable grade ≥3 toxicity and no treatment‑related deaths, supporting further comparative evaluation.